Researchers have discovered a possible target for cancer immunotherapy. The research, directed by Professor Massimiliano Mazzone, discovered that the CDA gene is one of the most elevated metabolic genes in immunotherapy-resistant cancer.Inhibiting this gene through pharmacological or genetic intervention resulted in improved T-cell infiltration, enhancing the efficacy of immunotherapy in PDAC, a type of pancreatic cancer.
Study done by VIB-KU Leuven Center for Cancer Biology and findings were published in Nature Cancer.
At present, immunotherapy treatments, including adoptive T-cell transfer, cancer vaccines and immune checkpoint blockade (ICB), represent a promising option for cancer patients.